Influence of anti-thymocyte globulin plasma levels on outcome parameters in stem cell transplanted children

Valentina Vogelsang; Anne Kruchen; Katharina Wustrau; Michael Spohn; Ingo Müller

doi:10.1016/j.intimp.2020.106371

Influence of anti-thymocyte globulin plasma levels on outcome parameters in stem cell transplanted children

Standard

Influence of anti-thymocyte globulin plasma levels on outcome parameters in stem cell transplanted children. / Vogelsang, Valentina ; Kruchen, Anne; Wustrau, Katharina; Spohn, Michael ; Müller, Ingo.

in: INT IMMUNOPHARMACOL, Jahrgang 83, 06.2020, S. 106371.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Vogelsang, V , Kruchen, A, Wustrau, K, Spohn, M & Müller, I 2020, 'Influence of anti-thymocyte globulin plasma levels on outcome parameters in stem cell transplanted children', INT IMMUNOPHARMACOL, Jg. 83, S. 106371. https://doi.org/10.1016/j.intimp.2020.106371

APA

Vogelsang, V., Kruchen, A., Wustrau, K., Spohn, M., & Müller, I. (2020). Influence of anti-thymocyte globulin plasma levels on outcome parameters in stem cell transplanted children. INT IMMUNOPHARMACOL, 83, 106371. https://doi.org/10.1016/j.intimp.2020.106371

Vancouver

Vogelsang V , Kruchen A, Wustrau K, Spohn M , Müller I. Influence of anti-thymocyte globulin plasma levels on outcome parameters in stem cell transplanted children. INT IMMUNOPHARMACOL. 2020 Jun;83:106371. https://doi.org/10.1016/j.intimp.2020.106371

Bibtex

@article{c1316fbcf4034c469ada285c694b4d53,

title = "Influence of anti-thymocyte globulin plasma levels on outcome parameters in stem cell transplanted children",

abstract = "INTRODUCTION: Allogenic hematopoietic stem cell transplantation is a curative option for malignant and non-malignant pediatric diseases. Serotherapy is often employed to avoid graft-versus-host disease (GvHD) on one hand and graft rejection on the other hand. Therapeutic drug monitoring is increasingly used to allow for more precise dosing especially in pediatric patients due to their specific pharmacological characteristics. Application of T-cell directed antibodies is not routinely monitored, but may benefit from more precise dosing regimens.METHODS: Two different preparations of rabbit anti-thymocyte globulin (rATG), Thymoglobuline{\textregistered} and ATG-F (Grafalon{\textregistered}), are frequently used to prevent GvHD in pediatric patients by in vivo T-cell depletion. Total rATG levels and active rATG levels were analyzed prospectively in pediatric patients undergoing HSCT. Clinical and laboratory outcome parameters were recorded.RESULTS: rATG levels were measured in 32 patients, 22 received thymoglobuline and 10 received ATG-F. The median total peak plasma level was 419.0 µg/ml for ATG-F and 60.4 µg/ml for thymoglobuline. For ATG-F, exposure could be predicted from the calculated dose more precisely than for thymoglobuline. Active peak plasma levels neither of ATG-F, nor of thymoglobuline correlated significantly with the number of lymphocytes prior to serotherapy. There was no significant difference in incidence of aGvHD, cGvHD, rejection, mixed chimerism or viral infections in the two cohorts. However, in our cohort, patients with high thymoglobuline exposure showed a compromised reconstitution of T cells.CONCLUSIONS: ATG-F and thymoglobuline show different pharmacological and immunological impact in children, whose clinical significance needs to be investigated in larger cohorts.",

author = "Valentina Vogelsang and Anne Kruchen and Katharina Wustrau and Michael Spohn and Ingo M{\"u}ller",

year = "2020",

month = jun,

doi = "10.1016/j.intimp.2020.106371",

language = "English",

volume = "83",

pages = "106371",

journal = "INT IMMUNOPHARMACOL",

issn = "1567-5769",

publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Influence of anti-thymocyte globulin plasma levels on outcome parameters in stem cell transplanted children

AU - Vogelsang, Valentina

AU - Kruchen, Anne

AU - Wustrau, Katharina

AU - Spohn, Michael

AU - Müller, Ingo

PY - 2020/6

Y1 - 2020/6

N2 - INTRODUCTION: Allogenic hematopoietic stem cell transplantation is a curative option for malignant and non-malignant pediatric diseases. Serotherapy is often employed to avoid graft-versus-host disease (GvHD) on one hand and graft rejection on the other hand. Therapeutic drug monitoring is increasingly used to allow for more precise dosing especially in pediatric patients due to their specific pharmacological characteristics. Application of T-cell directed antibodies is not routinely monitored, but may benefit from more precise dosing regimens.METHODS: Two different preparations of rabbit anti-thymocyte globulin (rATG), Thymoglobuline® and ATG-F (Grafalon®), are frequently used to prevent GvHD in pediatric patients by in vivo T-cell depletion. Total rATG levels and active rATG levels were analyzed prospectively in pediatric patients undergoing HSCT. Clinical and laboratory outcome parameters were recorded.RESULTS: rATG levels were measured in 32 patients, 22 received thymoglobuline and 10 received ATG-F. The median total peak plasma level was 419.0 µg/ml for ATG-F and 60.4 µg/ml for thymoglobuline. For ATG-F, exposure could be predicted from the calculated dose more precisely than for thymoglobuline. Active peak plasma levels neither of ATG-F, nor of thymoglobuline correlated significantly with the number of lymphocytes prior to serotherapy. There was no significant difference in incidence of aGvHD, cGvHD, rejection, mixed chimerism or viral infections in the two cohorts. However, in our cohort, patients with high thymoglobuline exposure showed a compromised reconstitution of T cells.CONCLUSIONS: ATG-F and thymoglobuline show different pharmacological and immunological impact in children, whose clinical significance needs to be investigated in larger cohorts.

AB - INTRODUCTION: Allogenic hematopoietic stem cell transplantation is a curative option for malignant and non-malignant pediatric diseases. Serotherapy is often employed to avoid graft-versus-host disease (GvHD) on one hand and graft rejection on the other hand. Therapeutic drug monitoring is increasingly used to allow for more precise dosing especially in pediatric patients due to their specific pharmacological characteristics. Application of T-cell directed antibodies is not routinely monitored, but may benefit from more precise dosing regimens.METHODS: Two different preparations of rabbit anti-thymocyte globulin (rATG), Thymoglobuline® and ATG-F (Grafalon®), are frequently used to prevent GvHD in pediatric patients by in vivo T-cell depletion. Total rATG levels and active rATG levels were analyzed prospectively in pediatric patients undergoing HSCT. Clinical and laboratory outcome parameters were recorded.RESULTS: rATG levels were measured in 32 patients, 22 received thymoglobuline and 10 received ATG-F. The median total peak plasma level was 419.0 µg/ml for ATG-F and 60.4 µg/ml for thymoglobuline. For ATG-F, exposure could be predicted from the calculated dose more precisely than for thymoglobuline. Active peak plasma levels neither of ATG-F, nor of thymoglobuline correlated significantly with the number of lymphocytes prior to serotherapy. There was no significant difference in incidence of aGvHD, cGvHD, rejection, mixed chimerism or viral infections in the two cohorts. However, in our cohort, patients with high thymoglobuline exposure showed a compromised reconstitution of T cells.CONCLUSIONS: ATG-F and thymoglobuline show different pharmacological and immunological impact in children, whose clinical significance needs to be investigated in larger cohorts.

U2 - 10.1016/j.intimp.2020.106371

DO - 10.1016/j.intimp.2020.106371

M3 - SCORING: Journal article

C2 - 32197227

VL - 83

SP - 106371

JO - INT IMMUNOPHARMACOL

JF - INT IMMUNOPHARMACOL

SN - 1567-5769

ER -